|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
DK0495421T3
(da)
|
1991-01-15 |
1996-12-09 |
Alcon Lab Inc |
Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
BR9307646A
(pt)
|
1992-12-17 |
1999-05-25 |
Pfizer |
Pirrolopirimidinas como antagonistas de crf
|
|
JPH0971528A
(ja)
*
|
1995-07-05 |
1997-03-18 |
Hayashibara Biochem Lab Inc |
抗腫瘍剤
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ES2168237T3
(es)
|
1996-02-07 |
2007-04-01 |
Neurocrine Biosciences, Inc. |
Pirazolopirimidinas como antagonistas de receptores de crf.
|
|
CA2242425C
(en)
|
1996-02-13 |
2006-07-18 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
AU747708B2
(en)
|
1996-07-24 |
2002-05-23 |
Du Pont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
|
PL332040A1
(en)
|
1996-08-28 |
1999-08-16 |
Pfizer |
Substitution 6,5-heterobicyclic derivatives
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
IL137019A
(en)
|
1998-01-28 |
2010-11-30 |
Du Pont Pharm Co |
2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
EP1040831A3
(en)
|
1999-04-02 |
2003-05-02 |
Pfizer Products Inc. |
Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
|
|
AU4203500A
(en)
|
1999-04-06 |
2000-10-23 |
Du Pont Pharmaceuticals Company |
Pyrazolopyrimidines as crf antagonists
|
|
FR2796380B3
(fr)
|
1999-07-15 |
2001-08-17 |
Sanofi Synthelabo |
Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
|
|
YU23602A
(sh)
|
1999-09-30 |
2004-09-03 |
Neurogen Corporation |
Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
|
|
HRP20010582A2
(en)
|
1999-12-08 |
2002-08-31 |
Pharmacia Corp |
Valdecoxib compositions
|
|
BR0111230A
(pt)
|
2000-05-31 |
2003-06-10 |
Astrazeneca Ab |
Composto, e, uso e processo para a preparação do mesmo
|
|
KR20030014425A
(ko)
|
2000-07-07 |
2003-02-17 |
앤지오젠 파마슈티칼스 리미티드 |
혈관 손상제인 콜치놀 유도체
|
|
EE200300015A
(et)
|
2000-07-07 |
2004-10-15 |
Angiogene Pharmaceuticals Limited |
Kolhinooli derivaadid kui angiogeneesi inhibiitorid
|
|
ES2282401T3
(es)
|
2001-03-13 |
2007-10-16 |
Bristol-Myers Squibb Pharma Company |
4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina.
|
|
WO2005020910A2
(en)
|
2003-08-27 |
2005-03-10 |
Pharmacia Corporation |
Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
|
|
US8304431B2
(en)
|
2003-12-02 |
2012-11-06 |
Pharmaneuroboost N.V. |
Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
JP4926720B2
(ja)
|
2003-12-22 |
2012-05-09 |
スミスクライン ビーチャム (コーク) リミテッド |
Crf受容体アンタゴニストおよびそれらに関連する方法
|
|
JP2008503444A
(ja)
|
2004-02-13 |
2008-02-07 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
Crf受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
|
|
CA2556160A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
CN101142217B
(zh)
|
2005-03-21 |
2010-12-08 |
伊莱利利公司 |
咪唑并哒嗪化合物
|
|
CA2644445A1
(en)
*
|
2006-03-29 |
2007-10-04 |
Velacor Therapeutics Pty Ltd |
Inorganic selenium for treatment of benign tumors
|
|
CN101516835A
(zh)
|
2006-07-19 |
2009-08-26 |
俄亥俄州立大学研究基金会 |
选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
|
|
MX2009003098A
(es)
|
2006-09-20 |
2009-04-01 |
Lilly Co Eli |
Compuestos de tiofen pirazolopirimidina.
|
|
KR101088239B1
(ko)
*
|
2006-09-20 |
2011-11-30 |
일라이 릴리 앤드 캄파니 |
Crf1 수용체 길항제로서의 티아졸 피라졸로피리미딘
|
|
US8952207B2
(en)
|
2007-09-11 |
2015-02-10 |
The University Of Houston System |
Copper-catalyzed C—H bond arylation
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
US20100203048A1
(en)
*
|
2008-04-30 |
2010-08-12 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the use of the treatment of cancer
|
|
TWI432435B
(zh)
|
2008-10-02 |
2014-04-01 |
Lilly Co Eli |
作為合成中間物之噻唑基-吡唑并嘧啶化合物及相關合成方法
|
|
EP4718073A3
(en)
|
2008-12-24 |
2026-07-29 |
Quest Diagnostics Investments LLC |
Mass spectrometry assay for congenital adrenal hyperplasia
|
|
US20110160168A1
(en)
|
2009-12-31 |
2011-06-30 |
Differential Drug Development Associates, Llc |
Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
|
|
US9750568B2
(en)
|
2012-03-08 |
2017-09-05 |
Medtronic Ardian Luxembourg S.A.R.L. |
Ovarian neuromodulation and associated systems and methods
|
|
JP2015516979A
(ja)
|
2012-04-23 |
2015-06-18 |
ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh |
Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト
|
|
KR20210064407A
(ko)
*
|
2014-01-21 |
2021-06-02 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
|
|
ES2964948T3
(es)
|
2015-03-31 |
2024-04-10 |
May Health Us Inc |
Métodos y sistemas para la manipulación de tejidos ováricos
|
|
BR112020002967A2
(pt)
|
2017-08-14 |
2020-08-11 |
Spruce Biosciences, Inc. |
antagonistas de receptor de fator de liberação de corticotropina
|
|
TWI803504B
(zh)
|
2017-08-14 |
2023-06-01 |
美商雲杉生物科技股份有限公司 |
促皮質素釋放因子受體拮抗劑
|
|
MX2020011344A
(es)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences Inc |
Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
|
|
PL3984523T3
(pl)
|
2018-12-07 |
2026-02-02 |
Neurocrine Biosciences, Inc. |
Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
|
|
US20200255436A1
(en)
|
2019-02-12 |
2020-08-13 |
Spruce Biosciences, Inc. |
Corticotropin releasing factor receptor antagonists
|
|
KR20220052927A
(ko)
|
2019-07-19 |
2022-04-28 |
스프루스 바이오사이언시스 인코포레이티드 |
선천성 부신 증식증의 치료 방법
|
|
JP2023537598A
(ja)
|
2020-08-12 |
2023-09-04 |
スプルース バイオサイエンシーズ,インク. |
多嚢胞性卵巣症候群を処置するための方法および組成物
|
|
EP4402142A4
(en)
|
2021-11-19 |
2025-07-23 |
Spruce Biosciences Inc |
CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION
|
|
US11708372B2
(en)
|
2021-11-19 |
2023-07-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|